Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02994147
Other study ID # AC-201CR-HA-001
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date March 21, 2017
Est. completion date October 2, 2019

Study information

Verified date July 2020
Source TWi Biotechnology, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Repeated joint bleeding leads to hemophilic arthropathy (HA), which manifests with chronic synovitis, cartilage damage and bony destruction. Currently available treatments of HA, including analgesics, NSAIDs, and hyaluronic acid, are predominantly directed toward the symptomatic relief of pain and inflammation, with no or little effect on joint cartilage degeneration. AC201CR, a control released formulation of AC-201, demonstrates anti-inflammatory effects by reducing NLRP3 inflammasome assembly. AC-201 is also unique in that it influences both the anabolism and catabolism of chondrocytes in vitro and has shown cartilage-sparing properties in animal studies. The study is designed to evaluate the joint structure-modifying and symptom-relieving effects, safety, and tolerability of AC-201CR in subjects with HA.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date October 2, 2019
Est. primary completion date April 18, 2019
Accepts healthy volunteers No
Gender Male
Age group 20 Years to 65 Years
Eligibility Inclusion Criteria:

1. Male age 20 to 65 years, inclusive

2. Diagnosis of Hemophilia A or B

3. Clinical diagnosis of hemophilic arthropathy in the knee(s) for at least 6 months

4. Pettersson score (based on X-ray) of 0 to 4 in at least one knee within 1 year of screening

5. IPSG (2012) overall score of 3 to 9 (based on MRI) in at least one knee at screening

6. Is able to read, understand, and sign the Informed Consent Form (ICF), communicate with the investigator, complete study diaries, and understand and comply with protocol requirements

Exclusion Criteria:

1. Total knee replacement in the primary knee

2. Presence of joint infections in the primary knee

3. Knee surgery within 6 months prior to screening in the primary knee

4. Intra-articular hyaluronic acid (IAHA) or platelet-rich plasma (PRP) injection in the primary knee within 6 months prior to screening

5. Use of any of the following medications after the screening visit:

1. NSAID injection (oral NSAIDs including COX-2 inhibitors allowed)

2. Glucosamine or chondroitin

6. History of high responder inhibitory antibodies to factor VIII or factor IX clotting factor, with titer >5 Bethesda units (BU), OR clinical evidence for presence of factor inhibitor

7. History of rheumatoid arthritis or gouty arthropathy

8. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) concentration >2x the upper limit of laboratory normal range (ULN), or bilirubin >1.5x ULN at screening

9. Positive test for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or TB

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Placebo
Placebo-only control study medication is the same formulation as active treatment without active ingredient
AC-201CR
The investigational product is formulated as controlled-release (CR) tablets

Locations

Country Name City State
Taiwan Tri-Service General Hospital Taipei

Sponsors (1)

Lead Sponsor Collaborator
TWi Biotechnology, Inc.

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in IPSG (MRI) score for primary knee Knee arthropathy will be evaluated according to the 2012 IPSG (International Prophylaxis Study Group) rating scale. This scale is an additive scale with maximum value up to 17 points, comprising 2 subscores of soft tissue changes (maximum 9 points) and osteochondral changes (maximum 8 points). 24 Weeks
Secondary Change from baseline in IPSG (MRI) score for non-primary knee 24 Weeks
Secondary Change from baseline in IPSG score by knee 48 Weeks
Secondary Change from baseline in IPSG component scores by knee 24 Weeks and 48 Weeks
Secondary Change from baseline in MRI-measured synovial thickness by knee 24 Weeks and 48 Weeks
Secondary Change from baseline in ultrasonographic synovial thickness by knee 24 Weeks and 48 Weeks
Secondary Change from baseline in ultrasonographic hyperemia score by knee 24 Weeks and 48 Weeks
Secondary Change from baseline in knee pain (by VAS) by knee 4, 12, 24, 28, 36 and 48 Weeks
Secondary Change from baseline in Short Form-36 score 24 Weeks and 48 Weeks
See also
  Status Clinical Trial Phase
Completed NCT01232634 - Validation of Ultrasound as a Diagnostic Tool for Assessment of Hemophilic Arthropathy of Knees and Ankles Phase 2
Completed NCT02601170 - Platelet-Rich Plasma Intra-Articular Injection in Treating Hemophilic Arthropathy N/A
Terminated NCT04684511 - Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy Phase 3
Recruiting NCT05517070 - Vitamin D Deficiency and Body Composition in the Patients With Hemophilia
Completed NCT04297696 - The Effects of Exercises on Gait in Hemophilic Individuals N/A
Completed NCT04535180 - Sarcopenia and Osteoporosis in the Patients With Hemophilia
Terminated NCT02569359 - Efficacy and Safety of Shea Nut Oil in Hemophilic Arthropathy N/A